“We are pleased to have received these final regulatory approvals for our pending acquisition of Hospira,” said Ian Read, Chairman and Chief Executive Officer, Pfizer. “We now look forward to combining our two companies and expect the transaction to close in early September.”
HR4U
HR4U
FE) today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Hospira (NYSE:HSP). The FTC’s clearance is contingent upon Pfizer’s commitment to divest four U.S. sterile injectable assets, including Acetylcysteine, Clindamycin, Voriconazole and Melphalan.